EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data

Takeshi Horii iD, Chikako Masudo, Yui Takayanagi, Yoichi Oikawa iD, Akira Shimada iD, Kiyoshi Mihara

Journal of Diabetes Investigation · 2024

DOI: 10.1111/jdi.14265 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Diabetes Investigation, 2024. Verfasst von Takeshi Horii und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Pharmacy, Musashino University, Tokyo, Japan. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Drug Monitoring. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adherence and treatment continuation rates of the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) semaglutide for both oral (O‐SEMA) and subcutaneous injection (SEMA‐SC) remain unknown in real‐world clinical practice. This retrospective observational study compared the 12 month adherence and treatment discontinuation of O‐SEMA and once‐weekly SEMA‐SC in patients with type 2 diabetes using a real‐world claims database. SEMA‐SC initiators were 1:1 propensity score‐matched to O‐SEMA initiators. Non‐adherence was defined as

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesDiabetes Mellitus, Type 2Hypoglycemic AgentsDrug MonitoringHumansMaleFemaleRetrospective StudiesMiddle AgedFollow-Up StudiesAdministration, OralAgedInjections, SubcutaneousJapanWithholding TreatmentEast Asian PeopleGlucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Stichwörter der Autor:innen

InjectionOralSemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Autor:innen und Institutionen

  • Department of Pharmacy, Faculty of Pharmacy, Musashino University, Tokyo, Japan.
  • Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan.

ORCID-Profile: Takeshi Horii, Yoichi Oikawa, Akira Shimada

Zitieren

APA

Horii, T., Masudo, C., Takayanagi, Y., Oikawa, Y., Shimada, A., & Mihara, K. (2024). Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14265

Vancouver

Horii T, Masudo C, Takayanagi Y, Oikawa Y, Shimada A, Mihara K. Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data. Journal of Diabetes Investigation. 2024. doi:10.1111/jdi.14265

BibTeX
@article{Horii2024,
  author = {Horii, Takeshi and Masudo, Chikako and Takayanagi, Yui and Oikawa, Yoichi and Shimada, Akira and Mihara, Kiyoshi},
  title = {Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data},
  journal = {Journal of Diabetes Investigation},
  year = {2024},
  doi = {10.1111/jdi.14265}
}
Kostenlos starten →